Additionally, potential therapeutic drugs targeting these key genes, including (+)-chelidonine, daunorubicin, and bisacodyl, were predicted.<h4>Conclusion</h4>GABARAPL1, FKBP5, PCDH9, and SLAMF8 are identified as potential biomarkers for RA, offering insights into future therapeutic strategies. This evidence concerns the gene GABARAPL1 and rheumatoid arthritis.